Haridwar Today

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Tendinopathy Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Tendinopathy, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Tendinopathy Market

• The market size for Tendinopathy in the 7MM was approximately USD 237.58 million in 2022 and is expected to increase significantly by 2036.

• The United States accounted for the highest Tendinopathy market size among the 7MM in 2025, compared to EU4 countries, the United Kingdom, and Japan.

• Epidemiological data indicate that 898 per 100,000 individuals in the United States are diagnosed with Achilles tendinopathy, with the highest incidence observed in those aged 50–59 years.

• As per secondary research, approximately 4.0% of Achilles tendinopathy patients progressed to rupture, highest in the 50–59 years age group (4.3%).

• In the UK, Achilles tendon rupture incidence is 0.008–0.018% per annum, with nearly 4,500 patients seeking medical help yearly.

• According to a real-world cohort study, the 12-month prevalence of tendon rupture and tendinopathy was 3.4% among patients with atherosclerotic cardiovascular disease and 1.9% in the overall population.

• Leading Tendinopathy companies, such as Causeway Therapeutics and New York R&D Center for Translational Medicine and Therapeutics, are developing novel Tendinopathy therapies that are expected to enter the market in the coming years.

• The promising Tendinopathy therapies in development include TenoMiR (CWT-001), TenoGen, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/tendinopathy-market

Key Factors Driving the Tendinopathy Market

Rising Prevalence of Tendon Injuries: Increasing participation in sports, fitness activities, and physically demanding occupations is contributing to a growing burden of tendon injuries and chronic tendinopathy cases globally.

Growing Aging Population: Older adults are particularly susceptible to tendinopathy due to age-related tendon degeneration, reduced healing capacity, and repetitive mechanical stress exposure.

Advancements in Regenerative Medicine: Growing research in biologics, platelet-rich plasma (PRP), extracellular shock wave therapy (ESWT), stem cell therapies, and microRNA-based therapies is reshaping the Tendinopathy treatment landscape.

Increasing Awareness and Improved Diagnosis: Enhanced awareness among healthcare providers and advancements in imaging modalities such as ultrasound and MRI are contributing to earlier and more accurate diagnosis of Tendinopathy.

Tendinopathy Competitive Landscape

Several Tendinopathy therapies are under development, led by Causeway Therapeutics’ TenoMiR (CWT-001), along with TenoGen and other regenerative therapies.

These therapies focus on restoring tendon healing pathways, reducing pain, improving tendon structure, and addressing the underlying degenerative pathology rather than providing only symptomatic relief.

Discover more about therapies set to grab major Tendinopathy market share @ Tendinopathy Treatment Landscape

Recent Developments in the Tendinopathy Market

• In October 2025, Causeway Therapeutics announced positive Phase II topline data for TenoMiR (CWT-001) in elbow tendinopathy. Correctly injected patients showed significant improvements in pain, function, and tendon structure.

• TenoMiR (CWT-001) is an investigational first-in-class microRNA-based therapy designed to restore microRNA-29a levels in injured tendon tissue.

• Causeway Therapeutics plans to initiate a Phase III trial of TenoMiR in lateral epicondylitis and a Phase II study in rotator cuff tendinopathy.

• In a study involving 90 patients receiving the target dose of TenoMiR or placebo, the therapy demonstrated significant reductions in pain and improvements in upper limb and elbow-specific function at 14, 28, and 90 days.

• VergenixSTR, developed by CollPlant, is approved in the EU for treating tendinopathy in various tendons, including elbow, rotator cuff, patellar, Achilles, and hand tendons.

What is Tendinopathy?

Tendinopathy is a chronic musculoskeletal disorder characterized by tendon pain, functional limitation, and structural abnormalities including collagen disorganization, neovascularization, and failed tendon healing. Commonly affected tendons include the Achilles tendon, patellar tendon, rotator cuff, elbow epicondyles, and gluteal tendons. The condition is associated with repetitive mechanical overload, aging, obesity, diabetes, sports injuries, and occupational stress. Diagnosis is primarily clinical and supported by imaging techniques such as ultrasound and MRI in uncertain cases.

Tendinopathy Epidemiology Segmentation

The Tendinopathy epidemiology section provides insights into the historical and current Tendinopathy patient pool and forecasted trends for the 7MM. The Tendinopathy market report proffers epidemiological analysis for the study period 2022–2036 segmented into:

• Total Incident Cases of Tendinopathy

• Gender-specific Cases of Tendinopathy

• Age-specific Cases of Tendinopathy

• Region-specific Cases of Tendinopathy

• Total Treated Cases of Tendinopathy

Scope of the Tendinopathy Market Report

• Therapeutic Assessment: Tendinopathy current marketed and emerging therapies

• Tendinopathy Market Dynamics: Key Market Forecast Assumptions of Emerging Tendinopathy Drugs and Market Outlook

• Key Companies: Causeway Therapeutics, New York R&D Center for Translational Medicine and Therapeutics, CollPlant, and others

• Key Therapies: TenoMiR (CWT-001), TenoGen, PRP Therapy, VergenixSTR, ESWT, Glyceryl Trinitrate, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Tendinopathy Market Access and Reimbursement

To know more about Tendinopathy companies working in the treatment market, visit @ Tendinopathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Tendinopathy Market Report Introduction

2. Executive Summary for Tendinopathy

3. SWOT Analysis of Tendinopathy

4. Tendinopathy Patient Share (%) Overview at a Glance

5. Tendinopathy Market Overview at a Glance

6. Tendinopathy Background and Overview

7. Tendinopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Tendinopathy

9. Tendinopathy Current Treatment and Medical Practices

10. Tendinopathy Unmet Needs

11. Tendinopathy Emerging Therapies

12. Tendinopathy Market Outlook

13. Country-Wise Tendinopathy Market Analysis (2022–2036)

14. Tendinopathy Market Access and Reimbursement of Therapies

15. Tendinopathy Market Drivers

16. Tendinopathy Market Barriers

17. Tendinopathy Appendix

18. Tendinopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services